An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- Acronyms ASPIRE
- Sponsors Allergan
- 20 Jul 2017 Planned End Date changed from 1 Sep 2017 to 11 Oct 2017.
- 20 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 11 Oct 2017.
- 08 Jun 2017 Interim results evaluating the 1-year onabotulinumtoxinA safety, effectiveness, and exploratory treatment utilization data, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.